Nanoways to overcome docetaxel resistance in prostate cancer

Aditya Ganju, Murali Yallapu, Sheema Khan, Stephen W. Behrman, Subhash Chauhan, Meena Jaggi

Research output: Contribution to journalReview article

43 Citations (Scopus)

Abstract

Prostate cancer is the most common non-cutaneous malignancy in American men. Docetaxel is a useful chemotherapeutic agent for prostate cancer that has been available for over a decade, but the length of the treatment and systemic side effects hamper compliance. Additionally, docetaxel resistance invariably emerges, leading to disease relapse. Docetaxel resistance is either intrinsic or acquired by adopting various mechanisms that are highly associated with genetic alterations, decreased influx and increased efflux of drugs. Several combination therapies and small P-glycoprotein inhibitors have been proposed to improve the therapeutic potential of docetaxel in prostate cancer. Novel therapeutic strategies that may allow reversal of docetaxel resistance include alterations of enzymes, improving drug uptake and enhancement of apoptosis. In this review, we provide the most current docetaxel reversal approaches utilizing nanotechnology. Nanotechnology mediated docetaxel delivery is superior to existing therapeutic strategies and a more effective method to induce P-glycoprotein inhibition, enhance cellular uptake, maintain sustained drug release, and improve bioavailability.

Original languageEnglish (US)
Pages (from-to)13-23
Number of pages11
JournalDrug Resistance Updates
Volume17
Issue number1-2
DOIs
StatePublished - Jan 1 2014

Fingerprint

docetaxel
Prostatic Neoplasms
Nanotechnology
P-Glycoprotein
Therapeutics
Pharmaceutical Preparations
Biological Availability
Compliance

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Cancer Research
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Nanoways to overcome docetaxel resistance in prostate cancer. / Ganju, Aditya; Yallapu, Murali; Khan, Sheema; Behrman, Stephen W.; Chauhan, Subhash; Jaggi, Meena.

In: Drug Resistance Updates, Vol. 17, No. 1-2, 01.01.2014, p. 13-23.

Research output: Contribution to journalReview article

@article{b67f62113f0b4ee9bb2557ea0cec53bc,
title = "Nanoways to overcome docetaxel resistance in prostate cancer",
abstract = "Prostate cancer is the most common non-cutaneous malignancy in American men. Docetaxel is a useful chemotherapeutic agent for prostate cancer that has been available for over a decade, but the length of the treatment and systemic side effects hamper compliance. Additionally, docetaxel resistance invariably emerges, leading to disease relapse. Docetaxel resistance is either intrinsic or acquired by adopting various mechanisms that are highly associated with genetic alterations, decreased influx and increased efflux of drugs. Several combination therapies and small P-glycoprotein inhibitors have been proposed to improve the therapeutic potential of docetaxel in prostate cancer. Novel therapeutic strategies that may allow reversal of docetaxel resistance include alterations of enzymes, improving drug uptake and enhancement of apoptosis. In this review, we provide the most current docetaxel reversal approaches utilizing nanotechnology. Nanotechnology mediated docetaxel delivery is superior to existing therapeutic strategies and a more effective method to induce P-glycoprotein inhibition, enhance cellular uptake, maintain sustained drug release, and improve bioavailability.",
author = "Aditya Ganju and Murali Yallapu and Sheema Khan and Behrman, {Stephen W.} and Subhash Chauhan and Meena Jaggi",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.drup.2014.04.001",
language = "English (US)",
volume = "17",
pages = "13--23",
journal = "Drug Resistance Updates",
issn = "1368-7646",
publisher = "Churchill Livingstone",
number = "1-2",

}

TY - JOUR

T1 - Nanoways to overcome docetaxel resistance in prostate cancer

AU - Ganju, Aditya

AU - Yallapu, Murali

AU - Khan, Sheema

AU - Behrman, Stephen W.

AU - Chauhan, Subhash

AU - Jaggi, Meena

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Prostate cancer is the most common non-cutaneous malignancy in American men. Docetaxel is a useful chemotherapeutic agent for prostate cancer that has been available for over a decade, but the length of the treatment and systemic side effects hamper compliance. Additionally, docetaxel resistance invariably emerges, leading to disease relapse. Docetaxel resistance is either intrinsic or acquired by adopting various mechanisms that are highly associated with genetic alterations, decreased influx and increased efflux of drugs. Several combination therapies and small P-glycoprotein inhibitors have been proposed to improve the therapeutic potential of docetaxel in prostate cancer. Novel therapeutic strategies that may allow reversal of docetaxel resistance include alterations of enzymes, improving drug uptake and enhancement of apoptosis. In this review, we provide the most current docetaxel reversal approaches utilizing nanotechnology. Nanotechnology mediated docetaxel delivery is superior to existing therapeutic strategies and a more effective method to induce P-glycoprotein inhibition, enhance cellular uptake, maintain sustained drug release, and improve bioavailability.

AB - Prostate cancer is the most common non-cutaneous malignancy in American men. Docetaxel is a useful chemotherapeutic agent for prostate cancer that has been available for over a decade, but the length of the treatment and systemic side effects hamper compliance. Additionally, docetaxel resistance invariably emerges, leading to disease relapse. Docetaxel resistance is either intrinsic or acquired by adopting various mechanisms that are highly associated with genetic alterations, decreased influx and increased efflux of drugs. Several combination therapies and small P-glycoprotein inhibitors have been proposed to improve the therapeutic potential of docetaxel in prostate cancer. Novel therapeutic strategies that may allow reversal of docetaxel resistance include alterations of enzymes, improving drug uptake and enhancement of apoptosis. In this review, we provide the most current docetaxel reversal approaches utilizing nanotechnology. Nanotechnology mediated docetaxel delivery is superior to existing therapeutic strategies and a more effective method to induce P-glycoprotein inhibition, enhance cellular uptake, maintain sustained drug release, and improve bioavailability.

UR - http://www.scopus.com/inward/record.url?scp=84902546498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902546498&partnerID=8YFLogxK

U2 - 10.1016/j.drup.2014.04.001

DO - 10.1016/j.drup.2014.04.001

M3 - Review article

VL - 17

SP - 13

EP - 23

JO - Drug Resistance Updates

JF - Drug Resistance Updates

SN - 1368-7646

IS - 1-2

ER -